autologous PRAME-targeting TCR-engineered T cells IMA203

A preparation of autologous T lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous PRAME-targeting TCR-engineered T cells IMA203 specifically recognize and bind to PRAME expressed on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the PRAME-expressing cancer cells. PRAME is overexpressed by a variety of cancer cell types.